Temporal dynamics of a predominant protease-inhibitor resistance mutation in a treatment naïve HCV-infected individual

The dramatic antiviral activities of drugs that specifically inhibit hepatitis C virus replication can be tempered by baseline mutations that confer resistance. We describe in an HIV-1/HCV coinfected individual the kinetics of an R155K mutation in HCV NS3 protease known to confer resistance to speci...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2009-03, Vol.199 (5), p.737-741
Main Authors: Kim, Arthur Y., Timm, Joerg, Nolan, Brian E., Reyor, Laura L, Kane, Katherine, Berical, Andrew C., Zachary, Kimon C., Lauer, Georg M., Kuntzen, Thomas, Allen, Todd M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The dramatic antiviral activities of drugs that specifically inhibit hepatitis C virus replication can be tempered by baseline mutations that confer resistance. We describe in an HIV-1/HCV coinfected individual the kinetics of an R155K mutation in HCV NS3 protease known to confer resistance to specific protease inhibitors. Longitudinal sequences revealed changes in the relative frequency of this variant independent of HCV replication levels, illustrating that this mutation coexists with wild-type strains in vivo in the absence of drugs. The persistence of drug resistance mutations argues for baseline resistance genotyping at initiation of therapy to accurately predict the efficacy of treatment.
ISSN:0022-1899
1537-6613
DOI:10.1086/596657